Alzamend Neuro, Inc.

Healthcare · Biotechnology · United States

Last price 1.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.84M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based th...